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Estimates of survival and costs are identical for cisplatin-
paclitaxel and cisplatin-gemcitabin. There was a higher
incidence of severe toxicities with cisplatin-gemcitabin,
but differences in QoL are still to be determined. 
Gemcitabin-paclitaxel is a dominated option with higher
costs and non-superior survival.
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OBJECTIVES: Colon cancer is one of the most common
malignancies in developed countries. Surgery is the
primary treatment modality for this disease. However, by
the time the patient presents with recurrent symptoms,
the disease is rarely curable by surgery even when com-
bined with other therapy. The aim was to assess the 
clinical and economic outcomes of OncoVAX®. therapy
in stage II colon cancer patients. METHODS: We have
completed a prospectively randomized, controlled clinical
trial of patients with Stage II colon cancer with active 
speciﬁc immunotherapy (ASI) using autologous tumor
cell with an immunomodulating adjuvant bacillus 
Callmette-Guérin (BCG) vaccine (OncoVAX) in an adju-
vant setting. Patients were randomized to either a control
group or (OncoVAX) therapy, after surgical resection of
the primary tumor and stratiﬁcation by stage of disease.
The cost analysis consisted of the direct health care costs.
For the model, the costs and probabilities of the several
interventions, disease stages and follow-up have been 
calculated. Survival and recurrence free survival were
used from the clinical study. Utility values were derived
from the literature. RESULTS: OncoVAX signiﬁcantly
improved survival and recurrence-free survival. The
number of life years in the OncoVAX group amounted to
6.96 and in the control group 6.17. The number of recur-
rence-free life years gained is approximately 1.14 more in
the OncoVAX group. The average costs per patient in the
OncoVAX group amounted to US$20,395 and in the
control group US$4,958. The costs per life year gained
amounted to US$19,541 and the costs per QALY
amounted to US$20,489. The total discounted cost-
effectiveness ratio was US$22,660 and the discounted
cost-utility ratio amounted to US$23,675 (discount rate:
4%). CONCLUSION: This study shows that OncoVAX
is an effective treatment modality for patients with stage
II colon cancer with a cost-effectiveness ratio in the range
of other oncological treatments.
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OBJECTIVES: Patients undergoing major orthopaedic
surgery are at risk of deep vein thrombosis, pulmonary
embolism and subsequent complications, some of which
may be fatal. For this reason post-operative prophylaxis
is recommended. Enoxaparin is the most frequently used
chemical prophylaxis in the UK. Fondaparinux is a novel
antithrombotic whose efﬁcacy has been demonstrated,
but whose cost-effectiveness has not been assessed. We
evaluated the cost-effectiveness of fondaparinux relative
to enoxaparin over a period of ﬁve years post-surgery.
METHODS: We modeled the impact of fondaparinux 
on patient outcomes and costs to the UK National 
Health Service (NHS). Outcomes are thromboembolitic
events (symptomatic deep vein thrombosis, pulmonary
embolism) and death. Data on the incidence of throm-
boembolitic events were derived from four randomised
clinical trials comparing enoxaparin with fondaparinux,
and from a review of the literature. Resource conse-
quences were estimated from a survey of UK hospitals
and discussions with a panel of clinical experts. Costs
were estimated using mean national costs to the NHS.
RESULTS: Fondaparinux dominates enoxaparin for all of
the surgery groups studied. The number of venous throm-
boembolic events (VTE) averted with fondaparinux is 15
per 1000 procedures (Total Hip Replacement), 19.5/1000
(Total Knee Replacement), 23.3/1000 (Hip Fracture
Surgery) and 19.2/1000 (All Procedures). The number of
VTE-related deaths averted is 0.8/1000 (THR), 0.8/1000
(TKR), 5.9/1000 (HFS) and 3.1/1000 (All Procedures).
Fondaparinux reduces expected cost per patient by £18
(THR), £41 (TKR), £30 (HFS) and £29 (All Procedures).
CONCLUSIONS: Compared with current practice in the
UK, fondaparinux is cost-effective. This conclusion is sen-
sitive to the relative price difference between enoxaparin
and fondaparinux, but it is robust to variations in all of
the other key parameters in the model. We estimate that
using fondaparinux could reduce NHS costs by £3.8
million annually.
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OBJECTIVES: Health care costs incurred for particular
diseases express priorities and can show future directions
for targeting resources. Because these costs are difﬁcult 
to obtain, there are hardly any reliable estimates in
Germany. The analysis intends to show a new approach
to estimate expenditures for CHD borne by the statutory
health insurance in Germany. METHODS: We identiﬁed
roughly 4 million individuals by pre-selected indicator
medications for ﬁve different diseases namely asthma,
diabetes, heart failure, hypertension and CHD. Individu-
als were selected for inclusion if these indicator medica-
tions were administered to them at least once in the year
1999. Indicator medications for CHD were nitrates and
molsidomine. Expenditures for individuals with CHD
were compared to average age- and gender-speciﬁc expen-
ditures for individuals without CHD. To ﬁnd the portion
of the difference, which could be attributed to CHD on
the one hand and to other diseases on the other hand, 
the strong correlation of disease occurrence was
accounted for in a stepwise procedure. RESULTS:
Approximately half of the cost difference between CHD-
cases and non-CHD cases could be explained by the pres-
ence of CHD and the other half by concurrent diseases.
The total costs attributed to CHD sum up to some $5
billion. As a whole the statutory health insurance spends
roughly $130 billion per year. CONCLUSIONS: Com-
pared with the total health care budget, CHD accounts
for roughly 4% of health care expenditures if inter-disease
correlations are considered. This amount seems low given
the fact that CHD accounts for more than 20% of deaths
in Germany. The strong interactivity of disease concern-
ing health care costs might imply that they should not be
looked at in isolation.
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OBJECTIVES: To compare hospital, procedural, and
ambulatory hypertension costs across eight countries
(Australia, Canada, France, Germany, Italy, Spain, UK
and the US) and document factors to consider when
making multinational comparisons. METHODS: Data
was obtained from health economics resources in each
country and an international literature search. Public and
private sources such as UK’s Royal London NHS Trust,
Personal Social Services Research Unit, and NHS Execu-
tive were used. Data tables captured four hypertension-
related events: Acute Myocardial Infarct (AMI),
Congestive Heart Failure (CHF), Stroke, and Renal
Failure (RF). All costs were converted into US Dollars for
the year 2000. RESULTS: There are considerable inter-
national variations in the hospitalization, procedural and
ambulatory hypertension treatment costs. These differ-
ences can be explained partially by the source of payment,
measurement of overhead, physician and hotel fees, and
prevailing practice patterns, as well as whether account-
ing costs or actual expenditures were used. US costs
appear to be higher for AMI, stroke and renal failure hos-
pitalizations, while CHF hospitalization costs are similar
across countries. The reported AMI hospitalization cost,
as a percentage of the US cost, ranges from 7.1% (UK)
to 43.5% (Spain). The UK and Australia appear to have
the lowest hospital-related and ambulatory costs across
all four events. Ambulatory costs for 1 year after an AMI,
CHF, transplantation or stroke hospitalization are highest
in the US. Typically the procedural and line item costs
were higher in the US than in other countries. Reported
CABG procedure costs ranged from 2.6% (France) to
51.8% (Italy) of US costs. CONCLUSIONS: We found
wide variation in captured and reported costs for hyper-
tension-related hospitalizations, procedures, and ambula-
tory care. Health services researchers should be cautious
when constructing or interpreting international compar-
isons, particularly in differentiating between actual cost
differences, differences in deﬁnition of services measured,
and national practice patterns.
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OBJECTIVES: The present study presents a Bayesian
cost-effectiveness analysis of HIV prevention in the
instance when costs and effects cannot be measured
directly. METHODS: A Bayesian approach to cost-
effectiveness analysis was illustrated using empirical data
from an HIV prevention randomized trial. We computed
incremental net health beneﬁt (INHB), and the analysis
was conducted from the societal perspective. Intervention
costs were estimated retrospectively. Clients were ran-
domized into an intervention (advocacy training) (N = 15)
or comparison condition (N = 15). Risk behavior data
were collected at baseline and three months after the end
of each intervention. In the Bayesian framework, we con-
sidered what could occur in a conceptual future study that
is an identical replicate to the one actually conducted.
Using posterior distribution of the behavior parameters,
we sampled 5000 replicates. With the use of a Bernoulli
model of HIV transmission, changes in the participants’
HIV risk were combined with HIV transmission parame-
ters (drawn from their respective prior distributions) and
